Articles On Hera Med (ASX:HMD)

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

It’s been a mixed week for the ASX but it has finished on a high. The ASX 200 closed 0.69% higher than yesterday, closing at 7,362 which marked a 3 week high but is still 3.5% above the all time high reached in mid-August. Travel stocks gai...

Local stocks posted a strong session on Thursday, as the ASX 200 climbed by around 1% while the microcap Emerging Markets index jumped again (+1.9%). Asian markets were buoyant more broadly, following a steady session on Wall Street overnig...

Pregnancy technology company HeraMED (HMD) enters a trading halt while it considers, plans and executes a capital raising The company will remain in the halt until October 18 or when an announcement is made released, whichever occurs firs...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Highlights Biotechnology firm Mesoblast extended its loss on disappointing earnings and dropped 5%. Graphite producer Volt Resources dropped despite successfully raising capital via share placement. Medical data and technology firm He...

Highlights The ASX 200 declined as much as 1% by lunchtime as investors awaited June quarter GDP figures. Australia’s Q2 GDP rose 0.7% in the June quarter. Barring energy, all indices were trading in the red, while healthcare declined...

ShareCafeHidden Gems Webinar Recap – EXL, WOA, OSX & HMD Catch up on the full webinar with presentations from  Elixinol Wellness (ASX: EXL), Wide Open Agriculture (ASX: WOA), Osteopore (ASX: OSX)  & HeraMED (ASX: HMD). Hidden Gems...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Summary Advanced Human Imaging has entered into a binding agreement with Jana Care to bring affordable digitally connected care to everyone. PainChek Infant has obtained the necessary regulatory approvals in multiple International mark...

The HeraMED Ltd (ASX: HMD) share price tanked today, closing 9% lower at 15 cents apiece. This came despite the company signed a pilot deal with Obstetrix Medical, one of the USA’s largest women’s and children’s healthcare providers. HeraM...

While there appeared to be several winners out of Budget 2021, few of them were on the ASX. The ASX 200 fell for the second day in a row losing 0.73 per cent to close at 7,045 points. Meanwhile the ASX Emerging Companies Index fell 0.51 per...

After closing at a record high yesterday the ASX retreated by nearly 1 per cent today. The ASX 200 lost 1.06 per cent to close at 7,097 points. The ASX Emerging Companies Index fared worse closing 2.3 per cent in the red – at 2,060 points....

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

HeraMED has announced a paid pilot with a leading medical provider for 100 expectant mothers. HeraMED’s (ASX:HMD) HeraCARE platform will be rolled out to 100 expectant mothers at WA’s Joondalup Health Campus as part of a landmark paid pilo...

The ASX fell again today, as risk-on sentiment continued to reign supreme in the markets. The ASX 200 fell 0.29 per cent, a smaller drop then yesterday but one that saw it close below 7,000 – at 6,997. Small caps fell by more, with the ASX...

The ASX 200 has finished the day in the red but is still above 7,000 points. The ASX 200 shed 0.68 per cent closing at 7,018 points while the ASX Emerging Companied Index fell 0.33 per cent, closing at 2,101 points. All sectors were in the...

The official publication of the American College of Obstetricians and Gynecologists has endorsed the results of a clinical trial into HeraMED’s foetal monitoring device. HeraMED (ASX:HMD) is a step closer to commercialisation following the...

Source:New Africa ,Shutterstock Summary COVID-19 had a significant impact on the HeraMED’s and Adherium’s first half 2021 results. However, the two players made critical developments during the period. HeraMED plans to expand further...

Summary With COVID-19 giving the opportunity to develop products, enhance services and conduct R&D, healthcare sector will be vigilantly gauged. Early spotting of a winning penny stock can offer considerable rewards to patient and...

Summary Amid growing adoption of digital platforms, Global Health registered a robust half-year performance. Total customer revenue for the period was up by 20% on PCP. The MasterCare platform for community health care providers exper...

Summary Global Health Ltd (ASX:GLH) said Lifecard Patient Portal is seeing high demand as health delivery organisations have embraced digital engagement with patients. Lifecard Patient Portal assists consumers and doctors in managing d...

Summary HeraMED’s partnership with eCare21 aims to fast-track awareness of HeraCARE and HeraBEAT across the US. Dimerix drug compound DMX-200 is set to be tested for COVID-19-induced ARDS in the global study. Dimerix is confident that...

Maternity-focused technology start-up HeraMED (ASX: HMD) has signed an agreement with US virtual care provider eCare21 to integrate its smart pregnancy monitoring solutions into eCare21’s software-as-a-service (SaaS) platform. Under the agr...

ASX telehealth stocks have had a solid six months, gaining 25 per cent, but there are warnings more has to be done to maintain the run. The breakout of COVID-19 resulted in wide-spread adoption of telehealth as medical professionals were fo...

Telehealth use has only continued to increase as COVID-19 wore on throughout May and June. Both listed and non-listed plays such as healthcare booking service HealthEngine saw demand rise exponentially as the pandemic broke out and this has...

Special Report: Maternity health digitiser HeraMED has raised serious cash from new and existing sophisticated and institutional investors to speed the rollout of its software platform HeraCARE. HeraMED (ASX:HMD) has raised $2.32m to speed...

Special Report: Maternal health tech company HeraMED is preparing for clinical trials in Australia with a new partnership. HeraMED (ASX:HMD) is getting ready to run clinical trials for its maternity care telehealth and remote monitoring so...

Special Report: Medical tech company HeraMED has signed an exclusive deal to distribute its foetal heart rate monitors in Australia. HeraMED (ASX:HMD) is accelerating its commercialisation strategy with an exclusive two-year Australian dist...

As we approach the middle of 2020, the investment environment surrounding the fallout from the COVID-19 pandemic remains complex. Along with threats, there will be plenty of opportunities. And it’s against that backdrop that this week marke...

VidCon is Stockhead’s new virtual conference series, bringing you expert insights, panel discussions and presentations on the most interesting and relevant investment sectors from leading analysts, listed small caps and industry participant...

Seasoned financial advisor, investment manager and corporate director Dr Nigel Finch is back in the radio booth for another instalment of The StockDoc Podcast. In this episode the good doctor sits down with Alexander Radke, general manager...

Stock Talk is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this first edition, host Dr Nigel Finch examines the coronavirus-induced boom of the telehealth industry. Populatin...

Maternity telehealth company HeraMED (ASX: HMD) revealed this morning in a conference call it was in “advanced discussions” regarding the expedited commercial roll-out of its platform across the US, UK, Australia and Israel. The company’s H...

HeraMED Limited (ASX:HMD), a medical technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, advised on Tuesday morning that it had received a significant uplift in inter...

The coronavirus-induced market carnage of the last few weeks has rattled plenty of investor nerves. But as with any major correction, some industries feel the brunt of the impact while for others, the dramatic shift presents an opportunity....

Special Report: HeraMed’s fast-tracked development process has paid dividends as its flagship product nears pilot testing. Medical technology company HeraMED’s (ASX:HMD) proprietary hybrid maternity care platform, HeraCARE, is now fully fu...

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

HeraMED (HMD) has appointed Alexander Radke as General Manager of its U.S. operations Alexander has previously held senior roles and has vast experience in the U.S. healthcare market He will use his expertise to develop the company’s strat...

2020 could be the year HeraMED (ASX:HMD) comes of age and it all has to do with its Artificial Intelligence (AI) platform, a cloud based machine learning software-as-a-service (SaaS) platform, known as OrionAI.

HeraMED (HMD) has received roughly 90,000 pregnancy monitoring records from the Mayo Clinic via their recent collaboration This is key in progressing the Orion AI platform, a cloud-based platform that analyses pregnancy records and detects...

Medical technology company, HeraMED Limited (ASX:HMD) has received approximately 90,000 pregnancy records from research and development collaborator the Mayo Clinic, which will be implemented into its OrionAI platform. This provides HeraMED...

Australian health care sector is one of the fastest growing, dynamic and highly diversified sectors having enormous potential to generate substantial returns for the Australian economy. A broad range of companies, from companies engaged in...

Technology undoubtedly holds a significant importance in each sector of the industry, more so than ever, and certainly health care sector is no different. Use of technologies in the health care sphere has emerged as a boon for doctors, rese...

Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system. Should this occur, under new CPT (Current P...

The Mayo Clinic has been established for more than 150 years, and employs more than 4500 physicians and scientists along with 54,000 allied health staff across 19 hospitals in five US states. It has been ranked No 1 hospital in the world fo...

Technology certainly plays a significant role in each segment of the industry, more so than ever, and health care sector is no different. Introduction of technologies in the health care domain emerged as the biggest blessing not only for pa...

Medical technology group, HeraMED Limited’s (ASX:HMD) distributor based in India has secured a commercial service partnership with Cloudnine Hospital Group to initiate a commercial pilot allowing expecting mothers in the Cloudnine network t...

HeraMED (ASX:HMD) has signed an agreement with Kinderheldin to add online midwifery service to be offered as HeraBEAT PLUS in Germany.